+34 620 10 75 37info@nanbiosis.com

Nanbiosis

You are here : Home / Archive for "GLP"

U10. Drug Formulation

Ciber bbn

U10. Drug Formulation

    • Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
    • Scientific Coordinator: Dr. Idoia Gallego Garrido idoiagallego@hotmail.com
    • Entities: Universidad del País Vasco (UPV/EHU)
    • Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
    • Phone: +34 653593042
    • Fax: +34 945 013040
    • Web: NANOBIOCEL UPV/EHU

UPV-EHU

Order request
U10. Drug Formulation-Particle_size_analyzerU10. Drug Formulation-Particle_size_analyzer
U10. Drug Formulation-LOTE 4 CALCEINA 10X 2BISU10. Drug Formulation-LOTE 4 CALCEINA 10X 2BIS
U10. Drug Formulation- Dissolution_rate_determination_equipmentU10. Drug Formulation- Dissolution_rate_determination_equipment

Description

Located at the Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Campus of Alava in Vitoria. The Unit is led by Prof. José Luis Pedraz and consists of large laboratories for cell culture, chromatography equipment, sample preparation and characterization, and one specific for scale preparation of pharmaceutical formulations. Recently the group has incorporated 3D bioprinters of the last generation with different technologies based on extrusion, inkjet, among others. It has also incorporated self-assembly equipment of nanoparticles based on microfluidic technologies.

This Unit can design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA, and vaccines using different methodologies based on micro and nano-medicine and the latter technology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this Unit. It counts on the most advanced equipment for micro and nanoencapsulation.

The Unit aims to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.

The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit10 counts with the most advanced equipment to cover the development for all the steps of the process.

One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U10. Services & Rates

Equipments

Active projects

  • Inhaled RNA Vaccines Against Tuberculosis. RTC: PMPTA/00143. Call: “Proyectos de I+D vinculados a la medicina personalizada y terapias avanzadas” from the joint initative ISCIII-CDTI. Funding agency: EU Next Generation Ministerio de Ciencia e Innovación CDTI. Duration: May 2024 – May 2026. Role: Partner.
  • Nanovectors for direct local-regional and controlled intravenous administration of antitumor drugs. Strategies to minimize adverse effects and maximize therapeutic response. ONCOLIBERYX. RTC: CPP2021-008362. Call: Convocatoria de ayudas para proyectos de colaboración público-privada 2021. Funding agency: Ministerio de Ciencia e Innovación. Duration: May 2022 – May 2024. Role: Partner.
  • Unlocking data content of Organ-On-Chips UNLOOC. RTC: 101140192-1. Call: HORIZON-KDT-JU-2023-1-IA-Topic-1. Funding agency: HORIZON Programme. Duration: January 2023 – May 2024. Role: Partner.
  • Optimization of a non-viral vector platform based on functionalized niosomes with nanodiamonds for gene therapy in cystic fibrosis. IP: Jose Luis Pedraz Muñoz and Gustavo Puras Ochoa. Funding agency: Ministerio de Ciencia e Innovacion. Funds: € 181.500. Duration: Jun 2020 – Jun 2023

Other projects

Title Fundin: Organism Call: Funding source Role
RTC-2016-4770-1 Development of a new bioadhesive for the treatment of Pterigium. Biotape
 Ministerio de Economía, Industría y Competitividad (MINECO) Retos Colaboración 2016 Partner
RTC-2016-5451-1 Development of Bioprinting and Bioink systems for cartilage and bone repair
 Ministerio de Economía, Industria y Competitividad (MINECO) Retos Colaboración 2016 Partner
GA: 783132 POSITION-II “A pilot line for the next generation of smart catheters and implants”
 Electronic Component Systems for European Leadership Joint Undertaking (JU) - ECSEL JU H2020-ECSEL-2017-1-IA-two-stage Partner
GA: 645991 DRIVE – Diabetes-Reversing Implants for Enhanced viability and long-term efficacy Unión Europea (Comisión Europea) H2020-NMP-2014-two-stage Partner
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017		 Coordinator

Ref Title Funding Organism Unit Role
RTC-2016-4770-1 DEVELOPMENT OF A NEW BIOADHESIVE FOR PTERIGIUM SURGERY. BIOTAPE MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. Participant
RTC-2016-5451-1 DEVELOPMENT OF BIOIMPRESSION SYSTEMS AND BIOTINES FOR THREE-DIMENSIONAL CARTILAGE AND BONE REGENERATION MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. Participant
RTC-2015-3303-1 Lipid solid nanoparticles for subcutaneous administration of antitumor marine compounds - UNDERLIPIDS MINISTERIO DE ECONOMIA Y COMPETITIVIDAD

Publications

2016

  • Grijalvo S., Puras G., Zarate J., Pons R., Pedraz J.L., Eritja R. et al. Nioplexes encapsulated in supramolecular hybrid biohydrogels as versatile delivery platforms for nucleic acids. RSC Advances. 2016;6(46):39688-39699.
  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Fleischer A. et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. International Journal of Pharmaceutics. 2016;498(1-2):263-273.
  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Bachiller D. et al. Stability study of sodium colistimethate-loaded lipid nanoparticles. Journal of Microencapsulation. 2016;33(7):636-645.
  • Garcia-Orue I., Gainza G., Gutierrez F.B., Aguirre J.J., Evora C., Pedraz J.L. et al. Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications. International Journal of Pharmaceutics. 2016;:-.
  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The role of helper lipids in the intracellular disposition and transfection efficiency of niosome formulations for gene delivery to retinal pigment epithelial cells. International Journal of Pharmaceutics. 2016;503(1-2):115-126.
  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain. Biomaterials. 2016;77:267-279.

News U10

10 Apr

Innovative eye drops offer new hope for Retinitis Pigmentosa patients

NANBIOSIS Unit 10 helps develop eye drops with adalimumab for retinitis pigmentosa, showing promising results in preclinical models. Vitoria, april 2025. A multidisciplinary team of researchers from the Centro de Investigación Biomédica en Red (CIBER), the Centro de Investigación Príncipe Felipe (CIPF), and the University of the Basque Country (UPV/EHU) has developed an innovative eye [...]

28 Feb

Advancing new treatments for Retinitis Pigmentosa within NANBIOSIS

NANBIOSIS Unit 10 develops lipid-based nanoparticles for gene and drug delivery, aiming for cost-effective, non-invasive treatments for retinitis pigmentosa. Vitoria, february 2025. Retinitis pigmentosa (RP) is a congenital rare disease that leads to progressive and irreversible vision loss. Both genetic mutations and inflammation contribute significantly to the progression of the disease. Researchers from the Drug [...]

11 Sep

Gene Therapy for Cystic Fibrosis: new inspiring scientific collaboration

Researchers are advancing gene therapies for cystic fibrosis using non-viral delivery methods, focusing on patient needs and innovative treatments. Basque Country, September, 2024 – As the world comes together to mark World Cystic Fibrosis Day, from NANBIOSIS we want to highlight the collaborative efforts between our Unit 10 “Drug Formulation” (U10), the University of the [...]

09 Sep

New gene therapy for Cystic Fibrosis: an interview with Lucía Enríquez

Vasque Country, September, 2024 – In this interview, Lucía Enríquez, a PhD researcher at NANBIOSIS Unit 10, discusses her work on gene therapies for cystic fibrosis, a genetic disease that mainly affects the lungs. Her research focuses on using non-viral vectors to deliver gene-editing tools, like Prime Editing, a variation of CRISPR-Cas9, to correct mutations [...]

27 Jun

Prof. Jose Luis Pedraz, new “Académico de Número” of the Spanish Royal National Academy of Pharmacy

Madrid, June, 2024 – In a distinguished ceremony held at the Spanish Royal National Academy of Pharmacy (Real Academia Nacional de Farmacia), Professor Jose Luis Pedraz Muñoz, a prominent figure at the University of the Basque Country, was officially inducted as an “Académico de Número”. The highest position within the Royal National Academy of Pharmacy. [...]

13 Nov

Rosa Hernández of the NanoBioCel group-NANBIOSIS U10 has received the Female Talent Award 2023 Women and Science

On Thursday, November 2, the Female Talent Award, in the category of Women and Science, was awarded to Rosa Hernández from the NanoBioCel group of CIBER BBN and the U10 Drug Formulation Unit. The award is given by AMPEA (Association of Professional and Business Women of Alava). In her award speech, Rosa Hernández, highlighted that [...]

08 Nov

Impactful research with NANBIOSIS participation in the Poster Tour of CIBER-BBN & CIBEREHD Annual Conference.

2023 CIBER-BBN Annual meeting has taken place at Santemar Hotel, in Santander during November 6-7. This year the format of our annual conferences has been changed towards a collective event scheme between the CIBER-BBN and CIBEREHD thematic areas. On Monday 6 the scientific sessions werecommon for EHD and BBN, with appealing contents for the mixed [...]

15 Oct

Developing Support Technologies for adressing traslational gaps in regenerative medicine.

On the 20th of October, CIBER-BBN group NanoBioCell – NANBIOSIS U10 Drug Formulation unit organises the Conference “Developping support technologies for adressing traslational gaps in regenerative medicine” by Dr. James-J Yoo. The Conference will take place in the Assembly hall of the Faculty of Pharmacy on Friday 20th of October, 2023 from 12:00 to 13:00, [...]

02 Oct

3D Printing and Bioprinting for Pharmaceutical and Medical Applications

Researchers of CIBER-BBN group NanoBioCell – NANBIOSIS U10 Drug Formulation unit Jose Luis Pedraz Muñoz, Laura Saenz del Burgo Martínez, Gustavo Puras Ochoa, Jon Zarate Sesma have edited the book “3D Printing and Bioprinting for Pharmaceutical and Medical Applications” The increasing availability and decreasing costs of 3D printing and bioprinting technologies are expanding opportunities to meet medical needs. 3D [...]

22 Jun

The role of microfluidics and 3D-bioprinting in the future of exosome therapy. A high impact review

Researchers of the NanoBioCel research group of the University of the Basque Country (UPV/EHU) and CIBER BBN, belonging to NANBIOSIS U10 Drug Formulation, Bioaraba, and CONICET Foundation of Argentina, have collaborated in a studio entitled: “The role of microfluidics and 3D-bioprinting in the future of the exosome therapy” which has been published in the journal [...]

• Read More

U19. Animal Modelling Unit

JUMISC

U19-CLINICAL TESTS LAB
• Read More

U21. Experimental operating rooms

JUMISC

U21. Experimental operating rooms

  • Scientific Director: Dr. Francisco M. Sánchez Margallo msanchez@ccmijesususon.com
  • Entities: Jesus Uson Minimally Invasive Surgery Centre (JUMISC)
  • Address: Carretera N-521, km 41, 10071 Cáceres
  • Phone: + 34 927 181 032
  • Web: JUMISC

Order request

U.21-Operating-Rooms-General-View-Microsurgery-RoomU.21-Operating-Rooms-General-View-Microsurgery-Room
U.21 Operating Rooms-Workstation detailU.21 Operating Rooms-Workstation detail

Description

Experimental operating rooms with high technology and high field instrumentation to promote methodological and translational research class in Biomedicine, both minimally invasive surgery and new procedures and in preclinical development for technical evaluation, medical devices, biomaterials, etc. Surgical facilities allow the development and use of small and large animal models for research and experimental surgery in several longitudinal areas: cardiovascular diseases, liver and digestive diseases, respiratory and systemic diseases, endocrinology and urology, gynecological and reproductive diseases, pediatric diseases, orthopedics and traumatology, ophthalmology and experimental surgery in all organ systems have the infrastructure for transplant development, implants, prosthesis, biomaterials, etc. under high quality experimental conditions that allow surgery, clinical follow up and obtaining biological samples in these models.

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

Unit 21. Services & Rates

Equipments

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
MAT2016-75611-R NANOMATERIALS REGENERATIVE IN SCENARIOS OF BONE PATHOLOGY: OSTEOPOROSIS AND INFECTION AgenciaEstatal de Investigación Participant

U21. Experimental operating rooms
• Read More

U22. Animal housing

JUMISC

U22. Animal housing

  • Scientific Director:  Axiel Torrescusa Bermejo atorrescusa@ccmijesususon.com
  • Entities: Jesus Uson Minimally Invasive Surgery Centre (JUMISC)
  • Address: Carretera N-521, km 41, 10071 Cáceres
  • Phone: + 34 927 181 032
  • Web: JUMISC

Order request

U.22 Animal Housing..U.22 Animal Housing..
U.22 Animal Housing.U.22 Animal Housing.
U.22 Animal HousingU.22 Animal Housing

Description

The JUMISC Animal Housing Unit provides services to companies and research groups in many preclinical trials. This unit advises designs and conducts preclinical validation on demand. It has qualified professionals to design, monitor and validate any type of biomedical study. In addition this unit has been certified by the Spanish Agency of Medicines and Health Products (AEMPS) for studies in “Dosing of test substance and non-clinical specimen drawing” and “Biocompatibility studies of medical devices”. These two new certifications are attached to existing “in vivo toxicity”, “Tolerance” and “Pharmacodynamics”. All these certifications allow NANBIOSIS members to perform studies to verify the effectiveness, safety and biocompatibility of nanotechnology under development. A most singular fact makes this unit is the possibility of housing, maintaining and supervising large animals for preclinical validations. This Service has extensive experience in handling and care of minipigs and what it entails use in preclinical studies.

Its perimeter area is 3,200 m2, and the net floor area is 2,865 m2. It has large rooms to house the experimental animals according to their species characteristics (age, sex, weight, breed) and to the research projects they are assigned to. Among the equipment and facilities include: rooms for the maintenance of large animals, rooms for maintaining small ruminants, barrier zone for maintenance of rodents under SPF conditions, integrated operating room within the barrier area, multi-use rooms for rodents and lagomorphs maintenance, room for receipt and handling of animals, quarantine rooms pre-experimental process, room to perform small procedures and cures and preparation rooms for large animals prior to the surgical area.

This unit has facilities with a perimeter area of 3,200 m2 and it has large rooms to house the experimental animals according to their species characteristics.

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

Unit 22. Services & Rates

Equipments

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

U22-Animal housing
• Read More